Breast Cancer

2:30
Highlighting a subset of TNBC for targeted therapy
Adrian Harris
2:47
Current treatment landscape of triple negative breast cancer
Adrian Harris
1:26
Breast cancer driver mutations in Saudi Arabia
Ahmed Saadeddin
2:15
Outlook for HR+/HER2- advanced breast cancer treatment
Ahmed Saadeddin
1:21
The challenges of treatment sequencing in HR+ breast cancer patients
Ahmed Saadeddin
0:51
Challenges in the treatment of mTNBC
Peter Schmid
1:01
The future therapeutic landscape of immunotherapy for mTNBC
Peter Schmid
2:52
IMpassion130 study: improvement in OS and PFS for IIT and PD-L1+ populations with mTNBC
Peter Schmid
3:38
SOLO-1: practice changing results for advanced ovarian cancer
Susana Banerjee
4:51
SOLAR-1: alpelisib plus fulvestrant for advanced breast cancer
Fabrice André
5:04
PALOMA-3: palbociclib and fulvestrant for HR-/HER+ metastatic breast cancer
Massimo Cristofanilli
7:08
IMpassion130: results of atezolizumab plus nab-paclitaxel for frontline TNBC
Peter Schmid
1:38
The importance of HCPs feeling comfortable and confident with biosimilars
Justin Stebbing
1:27
Education is key to improve confidence in biosimilars
Justin Stebbing
2:33
Positive results for trastuzumab biosimilar CT-P6 in HER2+ early breast cancer
Justin Stebbing
4:32
Smart app to allow patients to manage their side effects independently
Shereen Nabhani-Gebara
The content of VJOncology is intended for healthcare professionals